ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1801

Clinical Implications of Persistent Sinus Tachycardia in Systemic Lupus Erythematous: A Retrospective Study

Santosh Bhusal1, Bassam Alhaddad2, Douglas Einstadter3 and Stanley Ballou1, 1Rheumatology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH, 2Rheumatology, Premier Physicians, Westlake OH, Cleveland, OH, 3Medicine, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Antinuclear antibodies (ANA), heart disease and proteinuria

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Resting Sinus Tachycardia (ST) is found in approximately 50 % of patients with SLE. Unexplained episodes of intermittent ST could be a manifestation of disease activity. Approximately 13-15 % of patients, however, continue to have unexplained ST that persists beyond the duration of disease flare. The significance of this finding is still under investigation, but may be associated with physical deconditioning, higher SLEDAI scores or occult serositis. We conducted a retrospective study to further elucidate its clinical significance.

Methods: SLE was defined as patients fulfilling SLICC 2012 criteria. Persistent ST was defined as unexplained resting heart rate > 90 bpm in > 50 % of all outpatient visits; a minimum of 8 outpatient visits were required such that transient episodes of tachycardia were excluded. Also excluded were tachycardia episodes with potential explanation e.g. acute illness, severe pain, fever, acute anemia, hyperthyroidism, pregnancy and history of cardiac arrhythmias. A retrospective chart review was performed in patients with a diagnosis of SLE between January 2000 and December 2015. Patients meeting SLICC 2012 criteria and > 8 outpatient visits were dichotomized into groups with or without persistent ST. Multiple variables were compared: demographics; individual components of SLICC 2012 criteria at the first and the latest follow-up; laboratory tests including ENA, APL, ESR/CRP, anemia and nephritis class; pulmonary, cardiac and renal components of SLICC damage index; comorbidities including APS, hypertension, hyperlipidemia and history of deep vein thrombosis; and, hydroxychloroquine, angiotensin converting enzyme inhibitor and beta blocker use. Fisher’s exact test was used and two sided p value < 0.05 considered significant.

Results:  Charts of 375 patients were reviewed. 106 met inclusion criteria. 17 (16%) had persistent ST. At the time of statistical analysis, complete data was available in 16 patients with persistent ST and 61 patients without. The mean duration of follow up was 6.4 and 7.3 years respectively. Persistent ST was found to be associated with the following in univariate analysis: serositis at presentation (44% vs 14% P 0.017), proteinuria > 500 mg/24 hour at the latest follow up (63% vs 33% P 0.044) and anti-histone antibodies (75% vs 42% P 0.026). Quantitative analysis of maximal proteinuria revealed an association of persistent ST with any proteinuria > 500 mg/24 hr (63% vs 31% P 0.02) as well as nephrotic proteinuria > 3 gm/24 hr (44% vs 18% P 0.045). In addition, class 5 nephritis was more common (25% vs 5% P 0.031) in this group. Other variables trending towards significance include: active urinary sediment/> 5 RBCs/hpf at latest follow up (50% vs 23% P 0.059), anti-DNA antibodies (75% vs 46% P 0.0504) and APS (25% vs 8% P 0.08).

Conclusion: Unexplained persistent ST could be a meaningful clinical sign in SLE. Early in natural history, this may imply the presence of incipient serositis while later on, of an ongoing proteinuric renal disease. A novel finding of high prevalence of anti-histone antibodies in this subgroup needs further scrutiny to discern its significance.


Disclosure: S. Bhusal, None; B. Alhaddad, None; D. Einstadter, None; S. Ballou, None.

To cite this abstract in AMA style:

Bhusal S, Alhaddad B, Einstadter D, Ballou S. Clinical Implications of Persistent Sinus Tachycardia in Systemic Lupus Erythematous: A Retrospective Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/clinical-implications-of-persistent-sinus-tachycardia-in-systemic-lupus-erythematous-a-retrospective-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-implications-of-persistent-sinus-tachycardia-in-systemic-lupus-erythematous-a-retrospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology